Clinical trials: Women Diagnosed With Cancer
Infections, Papillomavirus, Cervical Cancer
Type Distribution of Human Papillomavirus in Adult African Women Diagnosed With Invasive Cervical Cancer
The aim of the study is to assess the distribution of the most frequent types of human papillomavirus in African women diagnosed with invasive cervical cancer.
- Trial name
- NCT01207999
- Testing
- Collection of cervical cancer tissue samples, Data collection
- Where
- 5 sites in Ghana, Nigeria and 1 more
- Volunteers
- 591 people
- Sponsor
- GlaxoSmithKline
Bladder Cancer
Study of Mycobacterium w in Superficial Transitional Cell Carcinoma of Bladder
The purpose of this study is to determine and compare the effect of this treatment on recurrence rate and to assess the toxicity in both arms of patients with STCC.
- Trial name
- STCC (NCT00694915)
- Testing
- Mycobacterium w, BCG (Bacillus Calmette-Guerin)
- Where
- 15 sites in India
- Volunteers
- 122 people
- Sponsor
- Cadila Pharnmaceuticals
Ovarian Cancer, Ovarian Neoplasms
A Study of Raludotatug Deruxtecan With or Without Bevacizumab as First-Line Maintenance Treatment in Non-HRD-Positive Advanced Ovarian Cancer (MK-5909-006, (ENGOT-ov102/GOG-3141/ REJOICE-Ovarian 04)
Researchers are looking for new ways to treat ovarian cancer (OC). Current treatment for OC may start with surgery to remove as much of the cancer as possible. After surgery, people may receive chemotherapy.
- Conditions
- Ovarian Cancer, Ovarian Neoplasms, Peritoneal Cancer, Fallopian Tube Cancer
- Trial name
- NCT07776691
- Testing
- R-DXd, Bevacizumab
- Where
- 13 sites in United States, Israel and 3 more
- Volunteers
- 802 people
- Sponsor
- Merck Sharp & Dohme LLC
Ovarian Neoplasms
A Diagnostic Test to Evaluate Cancer Risk Before Surgery in Women With an Ovarian Mass
Ovarian cancer is a serious health risk with the highest death rate among gynecological cancers. Unfortunately, it's only possible to definitively diagnose ovarian cancer after surgery, as there are no reliable tests to determine…
- Trial name
- NCT06566716
- Testing
- CleoDX ovarian cancer test
- Where
- 19 sites in United States
- Volunteers
- 1,000 people
- Sponsor
- Cleo Diagnostics Ltd
Bladder Cancer, Urothelial Carcinoma Bladder
Evaluating Bladder CARE™, a New Non-Invasive Urine Test, for Bladder Cancer Detection in Inconclusive Cases
The goal of this observational study is to learn about the performance of the Bladder CARE™ Assay in patients suspected of having bladder cancer with atypical cytology or equivocal cystoscopy results.
- Trial name
- NCT06870253
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Pangea Laboratory LLC
Epithelial Ovarian Cancer, Fallopian Tube Cancer
Study of Safety & Biological Activity of IP IMNN-001 (also Known As GEN-1) with Neoadjuvant Chemo in Ovarian Cancer
This dose escalation study will determine a maximum tolerated dose and/or optimal biological dose of GEN-1 for carboplatin/paclitaxel combination in newly diagnosed ovarian cancer.
- Conditions
- Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Trial name
- NCT02480374
- Testing
- IMNN-001
- Where
- 4 sites in United States
- Volunteers
- 18 people
- Sponsor
- Imunon
Small Cell Lung Cancer, Renal Cell Carcinoma (RCC)
Phase 2 Study for the Patient, Who Has Diagnosed With Small Cell Lung Cancer (SCLC) or Non Small Cell Lung Cancer (NSCLC) or Renal Cell Carcinoma (RCC) and Finished the First Line Stand Treatment , Need More Treatment
This trial is a Phase II trial designed to evaluate the safety and efficacy of using oral AL8326 , a multi-targeted receptor Tyrosine Kinase Inhibitor( TKI) , to recurrent, advanced, or metastatic small cell lung cancer (SCLC)…
- Conditions
- Small Cell Lung Cancer, Renal Cell Carcinoma (RCC), Non-Small Cell Lung
- Trial name
- NCT05363280
- Testing
- AL8326 40 mg, AL8326 60 mg, AL8326 80 mg--stopped
- Where
- 7 sites in United States, Spain
- Volunteers
- 80 people
- Sponsor
- Advenchen Pharmaceuticals, LLC.
Clear Cell Renal Cell Carcinoma
Piflufolastat F 18 PET/CT in Patients With Suspected, or at High Risk for Metastatic ccRCC
This study is being conducted to test whether an imaging technique called a "piflufolastat F 18 PET/CT" imaging scan can be used to diagnose and describe the extent of clear cell Renal Carcinoma in patients.
- Trial name
- HARRIER (NCT07084909)
- Testing
- piflufolastat F 18
- Where
- 2 sites in United States
- Sponsor
- Lantheus Medical Imaging
Ovarian Cancer, Fallopian Tube Cancer
Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer
This is a 1:1 randomized, open label, multi-center phase I/II trial to evaluate the safety, dosing, efficacy, and biological activity of adding IMNN-001 to chemotherapy + BEV compared to chemotherapy + BEV alone.
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Trial name
- MRD (NCT05739981)
- Testing
- Paclitaxel, Carboplatin, Bevacizumab
- Where
- 4 sites in United States
- Volunteers
- 30 people
- Sponsor
- Imunon
Clear Cell Renal Cell Carcinoma (ccRCC)
Evaluation of Safety, Pharmacokinetics, Distribution，Radiation Safety and Sensitivity/Specificity of PET/CT Imaging With 68Ga-NYM096 in Participants With IRM
68Ga-NYM096 is a carbonic anhydrase IX (CAIX)-targeted imaging agent that is under clinical development as a non-invasive diagnostic imaging agent for the detection of clear cell renal cell carcinoma (ccRCC).
- Trial name
- NCT07768306
- Testing
- 68Ga-NYM096 injection
- Volunteers
- 20 people
- Sponsor
- Norroy Bioscience Co., LTD
Renal Cell Carcinoma, Metastatic
Intratumoral Vaccination With Intuvax Pre-nephrectomy Followed by Sunitinib Post-nephrectomy vs Sunitinib Post-nephrectomy in Newly Diagnosed Metastatic Renal Cell Carcinoma (mRCC)
The purpose of this study is to compare tumor response, progression free survival (PFS) and overall survival (OS) in newly diagnosed mRCC patients treated with Intuvax (INN: ilixadencel) pre-nephrectomy followed by Sunitinib…
- Trial name
- MERECA (NCT02432846)
- Testing
- Intuvax (INN: ilixadencel), Sunitinib
- Where
- 28 sites in United States, Czechia and 7 more
- Volunteers
- 88 people
- Sponsor
- Mendus
Cervical Cancer
Human Papillomavirus (HPV) Type Distribution in Adult Women Diagnosed With Invasive Cervical Cancer in New Zealand
The aim of this study is to assess the distribution of the most frequent types of human papillomavirus in women diagnosed with invasive cervical cancer in New Zealand.
- Trial name
- NCT01328028
- Testing
- Testing of archived cervical cancer tissue samples, Data collection
- Volunteers
- 244 people
- Sponsor
- GlaxoSmithKline
Cervical Intraepithelial Neoplasia 3
Safety and Efficacy of GX-188E DNA Therapeutic Vaccine Administered by Electroporation After Observation
This study is to follow up on the change of immune response by measuring HPV type 16/18 E6 and E7 specific T cell response and lesion condition in subjects who have administered in DNA-based therapeutic vaccine.
- Trial name
- GX-188E (NCT02411019)
- Testing
- GX-188E
- Where
- South Korea
- Volunteers
- 67 people
- Sponsor
- Genexine, Inc.
Anovulation, Oligo-ovulation
Trial to Assess the Clinical Efficacy and Safety of MSJ-0011 in Inducing Ovulation in Anovulatory or Oligo-ovulatory Japanese Women
This is an open-label, parallel-group, randomized, multicenter Phase III trial to compare the efficacy and safety of a single 250 microgram (mcg) subcutaneous dose of MSJ-0011 to a single 5,000 international units (IU)…
- Conditions
- Anovulation, Oligo-ovulation, Hypothalamic-pituitary Dysfunction, Polycystic Ovarian Syndrome
- Trial name
- NCT01653743
- Testing
- MSJ-0011, urinary hCG (u-hCG), Follitropin alpha
- Where
- 6 sites in Japan
- Volunteers
- 81 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Breast Cancer, Head and Neck Squamous Cell Carcinoma
A Study to Evaluate ONM-100, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer
This study is to evaluate diagnostic performance, safety and timing of post-dose imaging of ONM-100, an intraoperative fluorescence imaging agent for the detection of cancer in patients with solid tumors undergoing routine…
- Conditions
- Breast Cancer, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer, Prostate Cancer
- Trial name
- NCT03735680
- Testing
- ONM-100
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- OncoNano Medicine, Inc.
HPV 16+ Confirmed Oropharynx Cancer and Cervical Cancer
A Study HB-201 in Patients With Newly Diagnosed HPV16+ Oropharynx or Locally Advanced Cervical Cancer
This Window of Opportunity clinical trial will examine the immunologic effects of the study agent HB-201 in the head and neck or cervical cancer, when administered by IV route.
- Trial name
- NCT04630353
- Testing
- HB-201 IV
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- AstraZeneca
Clear Cell Renal Cell Carcinoma
89Zr-TLX250 for PET/CT Imaging of ccRCC- ZIRCON Study
89Zr-TLX250 is under clinical development as a diagnostic agent targeting clear cell renal cell carcinoma.
- Trial name
- 89ZR-TLX250 (NCT03849118)
- Testing
- 89Zr-girentuximab
- Where
- 31 sites in United States, Australia and 6 more
- Volunteers
- 300 people
- Sponsor
- Telix Pharmaceuticals (Innovations) Pty Limited
Carcinoma, Ovarian Epithelial, Ovarian Neoplasms
Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery
Study to compare the safety and efficacy of oregovomab versus placebo, administered in combination with specific cycles of a standard six-cycle chemotherapy regimen (paclitaxel and carboplatin), for the treatment of subjects with…
- Conditions
- Carcinoma, Ovarian Epithelial, Ovarian Neoplasms, Ovarian Cancer, Ovarian Serous Adenocarcinoma
- Trial name
- FLORA-5 (NCT04498117)
- Testing
- Oregovomab, Paclitaxel, Carboplatin
- Where
- 148 sites in United States, Argentina and 12 more
- Volunteers
- 615 people
- Sponsor
- CanariaBio Inc.
Epithelial Ovarian Cancer, Fallopian Tube Cancer
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess the safety and efficacy of neoadjuvant carboplatin and mirvetuximab soravtansine in…
- Conditions
- Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Neoadjuvant
- Trial name
- NCT06890338
- Testing
- Carboplatin, Mirvetuximab Soravtansine, Bevacizumab
- Where
- 73 sites in United States
- Volunteers
- 140 people
- Sponsor
- AbbVie
Ovarian Neoplasms, Ovarian Cancer
A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
Researchers are looking for new ways to treat ovarian cancer (OC). Current treatment for OC may start with surgery to remove as much of the cancer as possible. After surgery, people may receive chemotherapy.
- Trial name
- TroFuse-021 (NCT07318558)
- Testing
- Sacituzumab tirumotecan, Bevacizumab, Rescue Medications
- Where
- 167 sites in United States, Argentina and 28 more
- Volunteers
- 900 people
- Sponsor
- Merck Sharp & Dohme LLC